Previous Close | 12.03 |
Open | 12.00 |
Bid | 11.90 x 800 |
Ask | 11.99 x 1100 |
Day's Range | 11.80 - 12.27 |
52 Week Range | 5.42 - 22.49 |
Volume | |
Avg. Volume | 288,614 |
Market Cap | 132.466M |
Beta (5Y Monthly) | 1.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.84 |
Earnings Date | Apr 01, 2024 - Apr 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for ANVS
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 211.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April. "We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our A
Investors need to pay close attention to Annovis Bio (ANVS) stock based on the movements in the options market lately.